JPH05163163A - Core-containing preparation - Google Patents
Core-containing preparationInfo
- Publication number
- JPH05163163A JPH05163163A JP35201291A JP35201291A JPH05163163A JP H05163163 A JPH05163163 A JP H05163163A JP 35201291 A JP35201291 A JP 35201291A JP 35201291 A JP35201291 A JP 35201291A JP H05163163 A JPH05163163 A JP H05163163A
- Authority
- JP
- Japan
- Prior art keywords
- core
- drug
- water
- coating
- coated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は有核製剤、とくには医薬
品分野において有用な、苦み等の不快な味が隠蔽され、
かつ有効成分の放出性に優れた有核製剤に関する。FIELD OF THE INVENTION The present invention can mask unpleasant tastes such as bitterness, which are useful in dry-coated preparations, particularly in the field of pharmaceuticals.
The present invention also relates to a dry-coated preparation having excellent release of the active ingredient.
【0002】[0002]
【従来の技術】従来から医薬品分野においては主薬の苦
み等の不快な味を解消することが重要な事項の一つとさ
れてきた。薬効の優れた薬物でも、その味が患者にとっ
て不快と感ずる場合、薬物コンプライアンスが低下して
充分な効果が得られないことがあり、その対策として種
々の方法が考えられてきた。2. Description of the Related Art Conventionally, in the field of pharmaceutical products, it has been an important matter to eliminate the unpleasant taste such as bitterness of the main drug. When even a drug having an excellent medicinal effect feels uncomfortable for the patient, the drug compliance may be lowered and a sufficient effect may not be obtained, and various methods have been considered as countermeasures.
【0003】この方法は、1)薬物の味を緩和するた
め、例えば糖類のように、その味とは違う種類の味を添
加する方法と、2)薬物の味を例えばエチルセルロース
やワックスなどの水不溶性被覆剤を使って被覆する方法
とに大別される。In this method, 1) a method of adding a taste different from the taste such as saccharides to alleviate the taste of the drug, and 2) adding a taste of the drug to water such as ethyl cellulose or wax. It is roughly divided into a method of coating using an insoluble coating agent.
【0004】1)の方法によるものは味の隠蔽効果が低
いため、主に不快な味の強度の低い薬物に利用されてい
る。2)の方法によるものには薬物を水不溶性被覆剤で
被覆したものと薬物を水不溶性被覆剤中に分散してマト
リックス状にしたものとがあって、前者は不快な味の強
度の強い薬物に対しても充分な隠蔽効果を持つが、後者
は製剤表面に薬物が露出した状態になるため、そのよう
な薬物にまで適用することはできない。また前者は患者
の口腔内での不快な味に対する隠蔽効果に優れている反
面、消化管に移行後の薬物放出性が一般に低いという欠
点がある。Since the method of 1) has a low taste-masking effect, it is mainly used for drugs having an unpleasant taste and low strength. In the method of 2), there are a drug coated with a water-insoluble coating agent and a drug dispersed in a water-insoluble coating agent to form a matrix. The former is a drug with a strong unpleasant taste. However, since the drug is exposed on the surface of the preparation, the latter cannot be applied to such drugs. The former is excellent in masking the unpleasant taste in the oral cavity of the patient, but has a drawback that the drug releasing property after transfer to the digestive tract is generally low.
【0005】これに対し、特開昭63−258809号公報には
内核粒を水溶性被膜で被覆し、これを更にカルボキシメ
チルエチルセルロースのような腸溶性被膜剤で被覆した
細粒が、また特開昭63−188021号公報にはポリビニルア
セタールジエチルアミノアセテートのような胃溶性被膜
剤で被覆した製剤がそれぞれ示されている。しかし、こ
れらの製剤は消化管移行後の薬物放出性が被覆剤のpH
溶解性に依存するため胃液や腸液のpHの変動に伴い薬
物の放出性も変動する恐れがある。On the other hand, in JP-A-63-258809, fine particles in which the inner core particles are coated with a water-soluble coating, which is further coated with an enteric coating agent such as carboxymethylethyl cellulose, are also disclosed. JP-A-63-188021 discloses a preparation coated with a gastric-soluble coating agent such as polyvinyl acetal diethylaminoacetate. However, in these formulations, the drug release after gastrointestinal transit is not
Since it depends on the solubility, the release property of the drug may change as the pH of the gastric juice or intestinal juice changes.
【0006】そこでエチルセルロースのようなpH非依
存性の水不溶性被膜剤で薬物を被覆した製剤の研究が進
められた。特開昭57-58631号公報にはこのような水不溶
性高分子と水溶性高分子とを含有する被覆用組成物で薬
物を被覆することにより、苦みが隠蔽され、かつ速放性
とした製剤が示されている。しかし、これを不快な味の
強い薬物へ適用することはできない。Therefore, research on a drug-coated preparation with a pH-independent water-insoluble film forming agent such as ethyl cellulose has been advanced. JP-A-57-58631 discloses a formulation in which bitterness is masked and an immediate release is obtained by coating a drug with a coating composition containing such a water-insoluble polymer and a water-soluble polymer. It is shown. However, it cannot be applied to drugs with an unpleasant taste.
【0007】特開平3−130214号公報には主薬と水膨潤
性物質とで造粒したものを核として、その周りにエチル
セルロースと水溶性高分子とで被覆することにより、不
快な味の隠蔽と速放性を持たせた製剤が示されている。
しかし、この核顆粒は大きさが不均一で全体としての粒
度分布幅が広く不定形顆粒を多く含むため、これを水不
溶性被膜剤で被覆しようとすると、均一な被膜ができに
くく不快な味を隠蔽するには多量に使用する必要があっ
た。In Japanese Patent Laid-Open No. 130214/1993, granules of a main ingredient and a water-swelling substance are used as cores, and the surroundings are covered with ethyl cellulose and a water-soluble polymer to mask unpleasant taste. Formulations with immediate release are shown.
However, since the core granules have a non-uniform size and a wide particle size distribution range as a whole and contain a large amount of irregularly shaped granules, if an attempt is made to coat them with a water-insoluble film-forming agent, a uniform film is difficult to form and an unpleasant taste is produced. It was necessary to use a large amount to conceal it.
【0008】[0008]
【発明が解決しようとする課題】したがって、本発明の
目的は苦み等の不快な味が隠蔽され、かつ有効成分の放
出性に優れた有核製剤を提供することにある。SUMMARY OF THE INVENTION Therefore, an object of the present invention is to provide a dry-coated preparation in which unpleasant taste such as bitterness is masked and the release of the active ingredient is excellent.
【0009】[0009]
【課題を解決するための手段】本発明による有核製剤
は、球形化処理を施した低置換度ヒドロキシプロピルセ
ルロースを核として、その周りに不快な味のする主薬を
被覆し、さらにその外側を水不溶性被膜剤で被覆してな
るものである。The dry-coated preparation according to the present invention has a spheroidized low-substituted hydroxypropylcellulose as a core, and an unpleasant-tasting main drug is coated around the core, and the outside is further coated. It is formed by coating with a water-insoluble coating agent.
【0010】以下、本発明を詳細に説明する。本発明の
有核製剤の製造に用いられる低置換度ヒドロキシプロピ
ルセルロース(以下、L−HPCとする)は、崩壊剤か
つ結合剤として一般に広く用いられている膨潤特性の大
きい物質である。本発明はこのL−HPCに球形化処理
を施しても水膨潤性が損なわれず依然として薬物放出性
にも優れていることを見出し本発明に到達した。The present invention will be described in detail below. The low-substituted hydroxypropyl cellulose (hereinafter referred to as L-HPC) used for producing the dry-coated formulation of the present invention is a substance having a large swelling property which is widely used as a disintegrating agent and a binder. The present invention has found that the water swelling property is not impaired even when the L-HPC is subjected to a spheroidizing treatment, and the drug releasing property is still excellent, and thus the present invention has been accomplished.
【0011】上記L−HPCのヒドロキシプロポキシル
基の置換度は、日本薬局方に記載の5.0〜16.0%の範囲
内のものであればよい。球形化後の核顆粒組成中のL−
HPCの含有量は90重量%以上であることが好ましく、
その他の成分として、例えば乳糖、でんぷん、結晶セル
ロース等の他の賦型剤が含まれていてもよい。The degree of substitution of the hydroxypropoxyl group of L-HPC may be within the range of 5.0 to 16.0% described in the Japanese Pharmacopoeia. L- in the nuclear granule composition after spheroidization
The content of HPC is preferably 90% by weight or more,
As other components, other excipients such as lactose, starch and crystalline cellulose may be contained.
【0012】L−HPCの球形化処理方法としては、
1)撹拌造粒機でL−HPCと水とを練合造粒後、乾
燥、篩分けを行って所望の粒度分布の製品を得る;2)
撹拌造粒機またはニーダーにてL−HPCと水とを練合
後、円筒押出機によって製粒を行い、さらにマルメライ
ザーでマルメ処理を行って、得られた顆粒を乾燥、篩分
けして同様の製品とする;3)L−HPCを水に分散さ
せた溶液を湿式粉砕し、その懸濁液をスプレードライヤ
ーで噴霧乾燥することにより製品を得る;などの方法が
挙げられる。As the spheroidizing method of L-HPC,
1) Kneading and granulating L-HPC and water with a stirring granulator, followed by drying and sieving to obtain a product having a desired particle size distribution; 2)
After kneading L-HPC and water with a stirring granulator or a kneader, granulation is performed with a cylindrical extruder, and then malm treatment is performed with a marumerizer, and the obtained granules are dried and sieved. 3) A solution in which L-HPC is dispersed in water is wet pulverized, and the suspension is spray-dried to obtain a product.
【0013】このようにして球形化処理された顆粒は、
顆粒の長径/短径の比で表される真球度が 1.3以下のも
のとなるので、次の工程でのコーチングが均一で精密に
行われ、不快な味の隠蔽効果に優れたものとなる。The granules thus spheroidized are
Since the sphericity represented by the ratio of major axis / minor axis of the granule is 1.3 or less, the coating in the next step is performed uniformly and precisely, and the effect of masking unpleasant taste is excellent. .
【0014】また、得られた顆粒は前述した篩分け操作
により所望の粒度範囲のもののみを選択採用できるので
粒度分布幅を小さくすることができる。この粒度分布幅
としては、例えば 200〜 300μm、 300〜 500μm、 5
00〜 700μmおよび 700〜 900μmの各群に分別した場
合に 300〜 500μmのものが全体の80重量%以上含まれ
るようなものが望ましく、これが80重量%未満の粒度分
布幅の広いものでは後工程での精密なコーチングが難し
くなる。なお、最終製品が細粒剤の場合には 200〜 300
μmまたは 300〜 500μmのものを主体とした粒度分布
のものを用いるのが好ましい。Further, since the obtained granules can be selected and employed only in the desired particle size range by the above-mentioned sieving operation, the particle size distribution width can be narrowed. The particle size distribution width is, for example, 200 to 300 μm, 300 to 500 μm, 5
When separated into groups of 00 to 700 μm and 700 to 900 μm, it is desirable that the content of 300 to 500 μm is 80% by weight or more of the whole, and if it is less than 80% by weight, the particle size distribution width is wide. Precise coaching is difficult. If the final product is a fine granule, 200 to 300
It is preferable to use the one having a particle size distribution mainly of μm or 300 to 500 μm.
【0015】球形化されたL−HPCの最終製品に対す
る割合は、水不溶性被膜の厚みによっても異なるが、40
〜90重量%であることが好ましい。これが40重量%未満
では薬物の放出性が低下し、90重量%を超えると不快な
味の隠蔽効果が期待できなくなる。The ratio of the spheroidized L-HPC to the final product depends on the thickness of the water-insoluble coating.
It is preferably about 90% by weight. If it is less than 40% by weight, the drug release property will be reduced, and if it exceeds 90% by weight, the effect of masking unpleasant taste cannot be expected.
【0016】他方、この顆粒を核として被覆する、本発
明の有核製剤に適切な不快な味のする主薬としては、例
えば、臭化プロパンテンリン、シメチジン等の抗潰瘍
剤、エリスロマイシン等のマクロライド系抗生物質、ペ
ニシリン誘導体やセファロスポリン誘導体等のβ−ラク
タム系抗生物質、クロルプロマジン等の向精神剤、ジゴ
キシン等の強心剤、スルピリン等の解熱剤などが挙げら
れる。これら主薬の配合量は、薬物の有効量および苦み
の度合いによって異なるが、最終製品に対して30重量%
以下とするのが望ましい。[0016] On the other hand, as an active ingredient having an unpleasant taste suitable for the dry-coated preparation of the present invention which coats the granules as cores, for example, anti-ulcer agents such as propantheline bromide and cimetidine, macromolecules such as erythromycin, etc. Ride antibiotics, β-lactam antibiotics such as penicillin derivatives and cephalosporin derivatives, psychotropic agents such as chlorpromazine, cardiotonic agents such as digoxin, and antipyretics such as sulpiline. Depending on the effective amount of the drug and the degree of bitterness, the content of these main drugs is 30% by weight based on the final product.
The following is preferable.
【0017】球形化されたL−HPCへの主薬の被覆、
造粒は流動層コーチング装置や遠心流動造粒装置を用い
た常法にしたがって行われる。その際、水溶性高分子や
乳糖、コーンスターチ、結晶セルロースなどの他の賦型
剤を加えてもよい。Coating of spheroidized L-HPC with active ingredient,
Granulation is performed according to a conventional method using a fluidized bed coating device or a centrifugal fluidized granulation device. At that time, other excipients such as a water-soluble polymer, lactose, corn starch, and crystalline cellulose may be added.
【0018】本発明の有核製剤の製造に際し最外層の形
成に用いられる水不溶性被膜剤としては、エチルセルロ
ース、ヒドロキシプロピルメチルセルロースフタレー
ト、ヒドロキシプロピルメチルセルロースアセテートサ
クシネート等の水不溶性高分子やワックス類等が挙げら
れるが、その中でもエチルセルロースが好ましい。The water-insoluble film forming agent used for forming the outermost layer in the production of the dry-coated preparation of the present invention includes water-insoluble polymers such as ethyl cellulose, hydroxypropylmethyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate, waxes and the like. Among them, ethyl cellulose is preferable among them.
【0019】この使用量はその種類によっても異なるが
最終製品に対して1〜15重量%が望ましい。これが1%
より少ないと不快な味の隠蔽ができず、15重量%より多
いと主薬の放出性が低下する。Although the amount used varies depending on the kind, it is preferably 1 to 15% by weight based on the final product. This is 1%
If it is less than the above range, the unpleasant taste cannot be masked, and if it is more than 15% by weight, the release of the active ingredient is lowered.
【0020】この被覆方法としては流動層コーチング装
置や遠心流動造粒装置を用いた常法にしたがって行われ
る。また、このときのコーチング液中にはクエン酸トリ
エチル、ポリエチレングリコール等の可塑剤、タルク等
の粘着防止剤、膜透過性を調節するための糖類、塩類、
水溶性高分子等の水溶性成分を適量添加してもよい。こ
のようにして作成された本発明による有核顆粒は、通常
顆粒剤または細粒剤の形態をとる。As the coating method, a conventional method using a fluidized bed coating device or a centrifugal fluidized granulation device is used. Further, in the coating liquid at this time, triethyl citrate, a plasticizer such as polyethylene glycol, an anti-adhesive agent such as talc, sugars for controlling the membrane permeability, salts,
A water-soluble component such as a water-soluble polymer may be added in an appropriate amount. The dry-coated granules according to the present invention thus produced usually take the form of granules or fine granules.
【0021】[0021]
【作用】本発明の有核製剤は経口投与されたときに最外
層にある水不溶性被膜によって主薬の不快な味が隠蔽さ
れ、顆粒の消化管移行後、水不溶性被膜からの水の浸透
によって顆粒の核にある球形化されたL−HPCが膨潤
し、水不溶性被膜を破壊することによって薬物が速やか
に外界へ放出されて薬効をもたらす。When the oral preparation of the present invention, the water-insoluble coating on the outermost layer masks the unpleasant taste of the main drug when orally administered, and after the granules are transferred to the digestive tract, water permeates through the water-insoluble coating. The spheroidized L-HPC in the nucleus of the swelling swells and destroys the water-insoluble film, so that the drug is rapidly released to the outside to bring about a drug effect.
【0022】[0022]
【実施例】次に、本発明を実施例および比較例によりさ
らに詳細に説明するが、本発明はこれらの実施例の記載
に限定されるものではない。 実施例1 真球度 1.0、 200〜 300μmの粒度のL−HPC 500g
を小型流動層コーチング装置 MODEL STREA-1(パウレッ
ク社製、商品名)に入れ、これに下記組成の液500gを
スプレー速度17g/分でコーチングして有核細粒を得
た。 ・ヒドロキシプロピルメチルセルロース TC-5R(信越化学工業社製、商品名) ‥‥‥ 4.0重量% ・臭化プロパンテリン ‥‥‥ 2.0 〃 ・塩化メチレン ‥‥ 47.0 〃 ・エタノール ‥‥ 47.0重量%EXAMPLES Next, the present invention will be described in more detail with reference to Examples and Comparative Examples, but the present invention is not limited to the description of these Examples. Example 1 500 g of L-HPC having a sphericity of 1.0 and a particle size of 200 to 300 μm.
Was placed in a small fluidized bed coating apparatus MODEL STREA-1 (manufactured by Paulec Co., Ltd., trade name), and 500 g of a liquid having the following composition was coated at a spray rate of 17 g / min to obtain fine particles with nuclei.・ Hydroxypropyl methylcellulose TC-5R (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) ‥‥‥ 4.0% by weight ・ Propantheline bromide ‥‥‥‥‥‥ 〃 ・ Methylene chloride 47.0 〃 ・ Ethanol ‥‥‥ 47.0% by weight
【0023】次に、この有核細粒 300gを前記小型流動
層コーチング装置に入れ、下記組成の液 150gをスプレ
ー速度15g/分でコーチングして目的の有核製剤を得
た。 ・エチルセルロース N-10 (信越化学工業社製、商品名)‥‥‥ 4.0重量% ・クエン酸トリエチル ‥‥‥ 0.2 〃 ・エタノール ‥‥‥95.8 〃Next, 300 g of the fine granules with nuclei were put into the above-mentioned small fluidized bed coating apparatus, and 150 g of a liquid having the following composition was coated at a spraying rate of 15 g / min to obtain a desired nucleated preparation.・ Ethyl cellulose N-10 (trade name, manufactured by Shin-Etsu Chemical Co., Ltd.) ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 0.2 〃 ・ Ethanol ‥‥‥‥ 95.8 〃
【0024】実施例2 実施例1において、エチルセルロース N-10 のコーチン
グ量を最終製品の5重量%としたほかは同様にして目的
の有核製剤を作製した。Example 2 A target dry preparation was prepared in the same manner as in Example 1 except that the coating amount of ethyl cellulose N-10 was 5% by weight of the final product.
【0025】実施例3 実施例1において、エチルセルロース N-10 のコーチン
グ量を最終製品の10重量%としたほかは同様にして目的
の有核製剤を作製した。Example 3 A target dry preparation was prepared in the same manner as in Example 1 except that the coating amount of ethyl cellulose N-10 was 10% by weight of the final product.
【0026】比較例1 L−HPC1kgと臭化プロパンテリン20gとを撹拌造粒
装置バーチカルグラニュレーター(パウレック社製、商
品名)に仕込み、ヒドロキシプロピルメチルセルロース
TC-5R(前出)の4重量%水溶液を添加しながら造粒を
行い、その造粒物を乾燥後、30メッシュ(500μm)の篩
で篩分けして細粒を作製した。この細粒に実施例2と同
様にエチルセルロース N-10 を最終製品の5重量%の量
でコーチングして有核製剤を作製した。Comparative Example 1 L-HPC (1 kg) and propantheline bromide (20 g) were placed in a stirring granulator vertical granulator (trade name, manufactured by Paulec Co.), and hydroxypropylmethyl cellulose was added.
Granulation was performed while adding a 4 wt% aqueous solution of TC-5R (previously described), and the granulated product was dried and then sieved with a 30 mesh (500 μm) sieve to produce fine particles. The fine granules were coated with ethyl cellulose N-10 in the same amount as in Example 2 in an amount of 5% by weight of the final product to prepare a dry-coated formulation.
【0027】各例で得られた有核製剤を下記の方法で評
価し、その結果を表1に示した。 1)官能試験(不快な味の隠蔽効果) 薬物量として15mg相当量の細粒を口に含み、苦みを感じ
始めるまでの時間を測定した。隠蔽時間が60秒以上のと
き不快な味が隠蔽されたと評価した。 2)溶出試験(D10分、D30分) 日本薬局方12、パドル法 50rpm 溶出液: 0.2%塩化ナトリウム水溶液 500ml、37℃。 D10分:10分後の溶出率。 D30分:30分後の溶出率。The dry-coated preparations obtained in each example were evaluated by the following methods, and the results are shown in Table 1. 1) Sensory test (masking effect of unpleasant taste) A fine drug equivalent to 15 mg was contained in the mouth as a drug amount, and the time until the start of feeling bitterness was measured. It was evaluated that the unpleasant taste was masked when the masking time was 60 seconds or more. 2) Dissolution test (D10 minutes, D30 minutes) Japanese Pharmacopoeia 12, paddle method 50 rpm Eluent: 0.2% sodium chloride aqueous solution 500 ml, 37 ° C. D 10 minutes: Elution rate after 10 minutes. D 30 minutes: Elution rate after 30 minutes.
【0028】 [0028]
【0029】以上の結果から実施例1〜3は薬物の苦み
が隠蔽され、かつ薬物放出性が優れた製剤であることが
判る。また、実施例3と比較例1とを比べると、球形化
処理されたL−HPCを核としてその周りに主薬を被覆
した実施例3の方が、L−HPC中に薬物を分散した核
を用いている比較例1よりも、不快な味の隠蔽効果と薬
物放出性のいずれにおいても優れていることが判る。From the above results, it is understood that Examples 1 to 3 are preparations in which the bitterness of the drug is masked and the drug release property is excellent. Further, comparing Example 3 with Comparative Example 1, Example 3 in which the spheroidized L-HPC was used as the core and the main drug was coated around the core had a core in which the drug was dispersed in L-HPC. It can be seen that, as compared with Comparative Example 1 used, both the effect of masking unpleasant taste and the drug release property are superior.
【0030】[0030]
【発明の効果】本発明の有核製剤は薬物の不快な味が隠
蔽され、かつ薬物放出性に優れている。The dry-coated preparation of the present invention masks the unpleasant taste of a drug and is excellent in drug release.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 武藤 泰明 新潟県中頸城郡頸城村大字西福島28番地の 1 信越化学工業株式会社合成技術研究所 内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Yasuaki Muto No. 28 Nishi-Fukushima, Chugoku Village, Nakakubiki-gun, Niigata Prefecture 1 Shin-Etsu Chemical Co., Ltd.
Claims (1)
ロピルセルロースを核として、その周りに不快な味のす
る主薬を被覆し、さらにその外側を水不溶性被膜剤で被
覆してなる有核製剤。1. A nucleated preparation comprising a spheroidized low-substituted hydroxypropylcellulose as a core, a core drug having an unpleasant taste is coated around the core, and the outside thereof is coated with a water-insoluble film-forming agent. .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35201291A JPH05163163A (en) | 1991-12-13 | 1991-12-13 | Core-containing preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35201291A JPH05163163A (en) | 1991-12-13 | 1991-12-13 | Core-containing preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05163163A true JPH05163163A (en) | 1993-06-29 |
Family
ID=18421177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP35201291A Pending JPH05163163A (en) | 1991-12-13 | 1991-12-13 | Core-containing preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05163163A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117845A1 (en) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
-
1991
- 1991-12-13 JP JP35201291A patent/JPH05163163A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005117845A1 (en) * | 2004-06-03 | 2005-12-15 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
US8420115B2 (en) | 2004-06-03 | 2013-04-16 | Taisho Pharmaceutical Co., Ltd. | Oral preparations and process for production thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6221402B1 (en) | Rapidly releasing and taste-masking pharmaceutical dosage form | |
US5082669A (en) | Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked | |
EP0941075B1 (en) | Rapidly releasing and taste-masking pharmaceutical dosage form | |
JP3470198B2 (en) | Composition for oral administration | |
JP3140764B2 (en) | Pulsatile once-daily release system of minocycline | |
CA2556514C (en) | Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same | |
JP2002533396A (en) | Sustained-release galantamine composition | |
WO2000024423A1 (en) | Sustained-release particles | |
JP3317444B2 (en) | Immediate release formulation with unpleasant taste masked | |
JP2000191519A (en) | Rapid release granule wherein unpleasant functional property of medicinally active ingredient is masked | |
JPH10203985A (en) | Production of taste-masking agent of antibacterial quinolone derivative | |
JP3221891B2 (en) | Rotary granulation and taste-masking coating for the preparation of chewable pharmaceutical tablets | |
JPH10504295A (en) | Pharmaceutical prescription | |
JP2003055199A (en) | Sustained release micropellet | |
JPS63258809A (en) | Fine granule having excellent releasing property of medicinally active ingredient and masked bitterness | |
JP2000053563A (en) | Rapid releasable fine granule having masked bitterness | |
EP1673064A1 (en) | Pharmaceutical composition comprising anticonvulsant with taste mask coating | |
JP3034592B2 (en) | Oral solid preparation and production method thereof | |
EP4035733A1 (en) | Granule having masked unpleasant taste and method for producing same | |
WO2002034268A1 (en) | Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-[2-[4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient | |
JPH05163163A (en) | Core-containing preparation | |
JPH0774151B2 (en) | Process for producing powder which masks unpleasant organoleptic properties of drug | |
JP3505734B2 (en) | Formulation for oral administration containing sodium ecabet | |
JP2001019635A (en) | Microcapsule containing sparingly water-soluble granule with bitterness as core substance and its production, and solid preparation containing such microcapsule | |
JPH05163137A (en) | Nucleus-containing granule |